Clinical trial

A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease

NCT07787169

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-09-01

PhasePHASE1

Study timeline

Study start (estimated)2026-09-01Date precision: month

Registry last updated2026-09-22

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Alzheimer Diseaseunresolved

Amyloidunresolved

Plaque, Amyloidunresolved

Healthy Volunteersunresolved

Interventions

Florbetapir F18OTHER

Florbetaben F 18OTHER

Sponsors & collaborators

Eli Lilly and Companylead sponsor

Mapped research locations

TampaFlorida, United States1 OrlandoFlorida, United States1 BeijingChina1 DecaturGeorgia, United States1 AnaheimCalifornia, United States1 IrvineCalifornia, United States1 Farmington HillsMichigan, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07787169 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.